Bastiaan van der Baan
Chief Executive Officer chez LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Fortune : 37 180 $ au 31/03/2024
Profil
Bastiaan van der Baan is the founder of thromboDx BV, which was founded in 2011.
He is currently the Chairman, President & Chief Executive Officer at Lixte Biotechnology Holdings, Inc. since 2022, an Independent Director at Tethis SpA since 2021, and a Venture Partner at Xgen Venture Sgr SpA since 2023.
Mr. van der Baan previously worked as a Sales Manager at Unilever Plc, Chief Clinical & Business Development Officer at Agendia NV, and Chief Clinical & Business Development Officer at Agendia, Inc. from 2012 to 2023.
He obtained a graduate degree from Wageningen University in 1996.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 11 000 ( 0,49% ) | 37 180 $ | 31/03/2024 |
Postes actifs de Bastiaan van der Baan
| Sociétés | Poste | Début |
|---|---|---|
| LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Chief Executive Officer | 26/09/2023 |
Tethis SpA
 Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Director/Board Member | 19/07/2021 |
Xgen Venture Sgr SpA
 Xgen Venture Sgr SpA Investment ManagersFinance Xgen Venture Sgr SpA (XGEN Venture) is a venture capital firm founded in 2021 by Federica Draghi, Paolo Fundarò and Daniele Scarinci. The firm is headquartered in Milan, Italy. | Private Equity Investor | 01/01/2023 |
Anciens postes connus de Bastiaan van der Baan
| Sociétés | Poste | Fin |
|---|---|---|
Agendia, Inc.
 Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Corporate Officer/Principal | 01/07/2023 |
| thromboDx BV | Founder | 01/01/2016 |
| UNILEVER PLC | Sales & Marketing | - |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Corporate Officer/Principal | - |
Formation de Bastiaan van der Baan
| Wageningen University | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| UNILEVER PLC | Consumer Non-Durables |
| LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Health Technology |
Tethis SpA
Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Health Technology |
| thromboDx BV | |
Xgen Venture Sgr SpA
Xgen Venture Sgr SpA Investment ManagersFinance Xgen Venture Sgr SpA (XGEN Venture) is a venture capital firm founded in 2021 by Federica Draghi, Paolo Fundarò and Daniele Scarinci. The firm is headquartered in Milan, Italy. | Finance |
